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Figure 1. Telomerase Activity in mTR1/1
INK4a2/2 Tumors and Design of In Vivo Tu-
morigenesis Studies
(A) TRAP assay of telomerase activity in four
independently derived mTR1/1 INK4a2/2 tu-
mors. Assays were run on 1000 cells for each
sample. NIH 3T3 cells were used as a positive
control for mouse telomerase activity. Heat
inactivation (H.I.) of samples was used as a
negative control for activity as indicated in
the figure. A PCR internal control (I.C.) was
used as indicated to obtain a relative estimate
of telomerase activity between samples.
(B) Mating scheme and design of in vivo
tumorigenesis studies. Mating of mTR1/2
INK4a2/2 mice produced mTR1/1 INK4a2/2
and G1 mTR2/2 INK4a2/2 mice in the ex-
pected Mendelian ratio. G1 mTR2/2 INK4a2/2
mice were crossed to produce the second
generation double null group, G2. Matings
within the same generation of mTR deficiency
produced the subsequent generation as indi-
cated. I and II refer to the two separate groups
of mice studied. G1 and G2 mice underwent carcinogenesis protocols at the same time in group I, while G3, G4, and G5 mice were studied
together in group II. mTR1/1 INK4a2/2 mice were used as a positive control comparison during carcinogenesis studies for group I and group II.
has been referred to as senescence by analogy to the are modulators of the pRB and p53 pathways, respec-
tively (reviewed in Sherr, 1998). p16INK4a expressionbehavior of human cells. Although mouse and human
cells share many morphological and biochemical fea- causes a G1 arrest by inhibiting cyclin-dependent ki-
nases 4 and 6, thus preventing pRB hyperphosphoryla-tures upon entry into senescence, the very long length
of mouse telomeres makes it unlikely that telomere tion, and S phase entry (Serrano et al., 1993). p19ARF
interacts with MDM2 and abrogates MDM2-inducedshortening provides a signal to activate the senescence
program. In the absence of a telomere sensing mecha- degradation of p53 through the ubiquitin/proteosome
pathway (Kamijo et al., 1998; Pomerantz et al., 1998;nism, the question of why telomerase is consistently
upregulated in immortalized and transformed mouse Stott et al., 1998; Zhang et al., 1998). While p19ARF has
been shown to mediate p53-dependent apoptosis in-cultures could relate to less stringent control of mouse
telomerase and TERT gene expression (Prowse and duced by oncogenic stimuli (de Stanchina et al., 1998;
Palermo et al., 1998; Radfar et al., 1998; Zindy et al.,Greider, 1995; Greenberg et al., 1998; Martin-Rivera et
al., 1998) and/or its regulation by proliferative factors 1998) and Rb deficiency (Bates et al., 1998; Pomerantz
et al., 1998), it is not required for activation of the p53such as the Myc oncoprotein (Wang et al., 1998; Green-
berg et al., 1999; Wu et al., 1999). Moreover, telomerase checkpoint function in response to DNA damage (Kamijo
et al., 1997; Stott et al., 1998).activation in these settings does not appear to be essen-
tial, since telomerase-deficient (i.e., homozygous null For purposes of this study, several features of the
INK4aD2/3 model are worth noting, including its highlyfor telomerase RNA, mTR2/2) MEFs immortalize in cul-
ture and form tumors following viral oncogenesis in nude penetrant cancer phenotype and the facts that INK4a2/2
MEFs are readily transformed by cellular oncogenes,mice (Blasco et al., 1997). On the other hand, telomere
maintenance in normal cells clearly plays a critical role exhibit a high rate of colony formation, and lack a senes-
cent arrest phase in culture (Serrano et al., 1996). Thesein preserving the genomic stability and long-term viabil-
ity of highly proliferative organ systems (Lee et al., 1998). findings have marked INK4a/ARF as a key tumor sup-
pressor locus encoding essential mediators of cellularSpecifically, defects in germ cell growth and survival,
uterine and intestinal atrophy, and impaired lymphocyte senescence. These experimental attributes, together with
intact DNA damage responses (Kamijo et al., 1997), es-mitogenesis, hematopoiesis, and wound healing were
evident in the later generations of mTR null mice (Lee tablish the INK4aD2/3 mouse as an ideal in vivo system
in which to assess the importance of telomere functionet al., 1998; Rudolph et al., 1999). Reports of proliferative
defects in mTR null ES cells after 300 population dou- in the tumorigenic process.
blings and cessation of growth at approximately 450
population doublings also point to the necessity of main- Results
taining telomeres via telomerase-dependent mecha-
nisms in cultured mouse cells (Niida et al., 1998). Impact of Telomerase and Telomere Function
on the INK4aD2/3 Cancer Phenotype of MiceThe compromise of proliferative organs in late-gener-
ation mTR null mice, and the evidence for possible re- Strong telomerase activation is correlated with tumori-
genesis in several mouse models (Chadeneau et al.,quirement of telomerase in tumorigenesis, prompted us
to evaluate the rate of tumor formation and cellular trans- 1995; Bednarek et al., 1996; Blasco et al., 1996; Broccoli
et al., 1996). To determine whether tumors derived fromformation in mice doubly null for INK4a (INK4a2/2) and
telomerase (mTR2/2). The INK4a/ARF locus produces INK4a2/2 null mice activate telomerase, the telomerase
activity assay (TRAP) (Kim et al., 1994) was used intwo distinct gene products, p16INK4a and p19ARF, which
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Figure 2. In Vivo Incidence of Tumor Forma-
tion and Survival in mTR2/2 Mice
(A and B) Mice underwent two-step carcino-
genesis protocols as described in Experi-
mental Procedures. The number of mice ana-
lyzed for each genotype, tumor incidence and
latency, and survival during the 16-week
study is indicated.
(C) Representative histology of tumor sam-
ples for mTR1/1 INK4a2/2 and G5 mTR2/2
INK4a2/2 groups. Aggressive fibrosarcomas
and B cell lymphomas are revealed for both
groups by hematoxylin and eosin staining of
paraffin-embedded sections.
INK4a2/2 tumors arising spontaneously or induced after al., 1996; see Experimental Procedures). To compare
more precisely the cancer incidence of mTR1/1 INK4a2/2carcinogenesis. In all tumors tested (five fibrosarcomas
and three B cell lymphomas), telomerase activity was mice with that of the G1-G5 mTR2/2 INK4a2/2 mice, mice
generated during the same period were monitored indetected at levels greater than those observed in non-
transformed NIH 3T3 fibroblasts (for representative ex- parallel (Figure 1B). In the first study (Figure 2A), mTR1/1
INK4a2/2 mice were compared with G1 mTR2/2 INK4a2/2amples, see Figure 1A). The much lower levels in non-
transformed mouse cells and consistent activation of and G2 mTR2/2 INK4a2/2 mice; while in the second
phase (Figure 2B), another group of mTR1/1 INK4a2/2telomerase in the eight INK4a2/2 tumors support the use
of this model to determine the role of telomerase and mice was compared with G3 through G5 mTR2/2
INK4a2/2 mice.telomere function in the development of primary solid
and lymphoid tumors. In the first investigation, the incidence, latency, clinical
behavior, and histological grade of primary tumors wereSuccessive generations of mice doubly null for mTR
and INK4a were mated to yield large cohorts of mice remarkably similar among the mTR1/1 INK4a2/2 and G1-
G2 mTR2/2 INK4a2/2 groups (Figure 2A). In the secondpossessing progressively shorter telomeres (Blasco et
al., 1997, and data not shown). Specifically, intercrosses set of experiments, a modest reduction in tumor inci-
dence was first evident in the G3 mTR2/2 INK4a2/2 groupbetween mTR1/2 INK4a2/2 mice produced the first gen-
eration of mTR2/2 INK4a2/2 mice (termed G1 mTR2/2 and became more marked in the G4 and G5 mTR2/2
INK4a2/2 groups (Figure 2B). Specifically, tumors devel-INK4a2/2). These G1 mTR2/2 INK4a2/2 mice were then
intercrossed to produce second-generation mTR2/2 oped in 16 of 25 (64%) mTR1/1 INK4a2/2 mice, compared
to 13 of 42 (31%) for the G4 and G5 mTR2/2 INK4a2/2INK4a2/2 mice (termed G2 mTR2/2 INK4a2/2) and so on
(Figure 1B). This mating strategy was pursued until the groups combined. Compared to the wild-type mTR co-
hort, the decrease in tumor formation was statisticallyfifth generation, at which point diminished fecundity pre-
cluded the production of G6 mTR2/2 INK4a2/2 mice (Lee significant for G4 mTR2/2 INK4a2/2 (p 5 0.0407), G5
mTR2/2 INK4a2/2 (p 5 0.0175), and G4 and G5 mTR2/2et al., 1998). As reported previously, INK4a2/2 mice are
highly cancer prone, exhibiting high rates of fibrosarco- INK4a2/2 combined (p 5 0.0083). The distribution of
tumor types was similar in all groupsÐ11 fibrosarcomasmas and B cell lymphomas following exposure to a two-
step DMBA/UVB carcinogenesis protocol (Serrano et and 5 B cell lymphomas confirmed in the mTR1/1
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INK4a2/2 mice and 9 fibrosarcomas and 4 B cell lympho-
mas diagnosed in the G4-G5 mTR2/2 INK4a2/2 mice.
Notably, despite a reduction in tumor incidence, the
histological appearance (tumor grade and severity) of
the 8 G4 and G5 mTR2/2 INK4a2/2 tumors analyzed
was indistinguishable from that of the mTR1/1 INK4a2/2
tumors analyzed (Figure 2C). The reduction in tumor
incidence in the later generations was also correlated
with an increase in survival, although a definitive cause
of death due to tumor burden was not always possible
to establish in all cases. Correspondingly, while only 3
of 25 (12%) mTR1/1 INK4a2/2 mice were alive at the end
of the experiment, 4 of 12 (33%) G3 mTR2/2 INK4a2/2;
7 of 16 (44%) G4 mTR2/2 INK4a2/2; and 14 of 26 (54%) G5
mTR2/2 INK4a2/2 mice survived. This increasing trend
in survival was significant by the log rank test when
comparing survival curves between mTR1/1 INK4a2/2
and G5 mTR2/2 INK4a2/2 (p 5 0.0052) or G4 1 G5
mTR2/2 INK4a2/2 (p 5 0.0072) groups. The decreased
tumors and increased survival in G4 and G5 mTR2/2
INK4a2/2 mice suggest that the significant telomere
shortening and loss of telomere function in late-genera-
tion mTR2/2 animals reduces cancer incidence in vivo
in mice homozygous for the INK4aD2/3 allele.
Impaired Cellular Growth and Colony Formation in
Late-Generation mTR2/2 INK4a2/2 MEF Cultures
The reduction in tumorigenesis in the G4-G5 INK4a2/2 Figure 3. Decreased Colony Formation in G5 mTR2/2 INK4a2/2
mice could relate to an intrinsic growth defect in the MEFs
developing cancer cell or to an inability of the host to (A) Colony formation assay revealing diminished ability of G5 mTR2/2
provide a supportive environment for tumor formation. INK4a2/2 MEFs to form detectable colonies following seeding at
3500 cells per 6 well plate and 8 days in culture. Note the diminishedWith respect to the latter, the host capacity required
intensity of the colonies that appear for G5 mTR2/2 samples (bottomfor tumorigenesis often necessitates robust proliferative
three panels) in comparison to mTR1/1 samples (top panel).responses (such as angiogenesis); it is therefore possi-
(B) Graphic illustration of the mean number of colonies appearing
ble that the loss of telomere function in surrounding for each MEF culture per 6-well plate. Each bar represents the mean
support cells could underlie the impaired tumorigenesis of three independent experiments.
in the G4-G5 INK4a2/2 mice. Thus, to compare more
directly the intrinsic growth and tumorigenic potential
of G5 INK4a2/2 derived cells, primary mouse embryonic the INK4a2/2 phenotype, short dysfunctional telomeres
fibroblasts (MEFs) were isolated and analyzed in culture are associated with a severe defect in growth and inabil-
for colony formation and for susceptibility to transforma- ity to escape senescence/crisis (see below).
tion by cellular oncogenes.
Colony formation following low-density seeding has Oncogenic Resistance of Late-Generation
been used as a quantitative assay to measure the capac- mTR2/2 INK4a2/2 Cells
ity of single cells to proliferate beyond senescence Focus formation following c-Myc and H-RASG12V cotrans-
checkpoints and hence serves as an indicator of prolifer- fection provides a quantitative measurement of transfor-
ative and immortalization potential (Kraemer et al., 1986; mation potential. Previous studies have established that
Conzen and Cole, 1995; Serrano et al., 1996). We have INK4a2/2 MEFs generate a high number of Myc/RAS-
shown previously that INK4a2/2 MEFs exhibit a greater induced transformed foci and that Myc/RAS oncogenic
than 200-fold increase in the rate of colony formation activity can be modulated by addition of genetic modifi-
relative to INK4a1/1 controls (Serrano et al., 1996). This ers to the cotransfection (e.g., Pomerantz et al., 1998).
high rate of colony formation affords an opportunity to As anticipated, several independent cotransfections
uncover a potential negative impact of telomere shorten- demonstrated an equivalent number of Myc/RAS-induced
ing on proliferation and immortalization. In multiple inde- foci in the mTR1/1 INK4a2/2 and G1-G2 mTR2/2 INK4a2/2
pendently derived cultures, G5 mTR2/2 INK4a2/2 MEFs cultures (Figure 4A, G1 mTR2/2 INK4a2/2 not shown). In
showed a greatly reduced ability to form colonies (Fig- contrast, all independently derived G5 mTR2/2 INK4a2/2
ures 3A and 3B). The sole exception was one sub- cultures exhibited 1.5- to 40-fold reductions in the num-
clone, G5.7 mTR2/2 INK4a2/2, that produced a similar ber of Myc/RAS foci relative to mTR 1/1 INK4a2/2 con-
number of colonies as mTR1/1 INK4a2/2 controls (Figure trols (Figures 4A and 4B). Foci derived from the G5
3A); however, these colonies were less dense and ap- mTR2/2 INK4a2/2 MEFs typically appeared 1 day later
peared senescent upon microscopic inspection (data on average and were often smaller in size than those
not shown). Together, these results indicate that, while derived from mTR1/1 INK4a2/2 cells. The observed re-
ductions in the rate of Myc/RAS focus formation forthe absence of telomerase per se has no direct effect on
Telomerase Deficiency Impairs Tumorigenesis In Vivo
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Figure 4. mTR Partially Rescues Myc/RAS Transformation of G5 mTR2/2 INK4a2/2 MEFs
(A) Graphic illustration of the number of foci per 10 cm plate 9 days following transfection of oncogenes Myc 1 RAS and either empty vector
(hatched) or mTR (black).
(B) Representative plates of the same MEF culture transfected with Myc 1 RAS 1 empty vector or mTR. Plates were stained with 0.1% crystal
violet.
(C) Growth of transformed cells in SCID mice. Entire plates transformed with Myc 1 RAS 1 vector (left) or mTR (right) were trypsinized and
5 3 105 cells were injected subcutaneously into SCID mice. Pictures were taken 12 days following injection.
late generations of mTR2/2 INK4a2/2 MEFs suggest that of tumor formation in vivo was examined in tumor trans-
plantation assays. Cells (1 3 106) were harvested fromshort telomeres attenuate the high transformation effi-
a plate containing foci generated from cultures cotrans-ciency of INK4a deficiency.
fected with Myc/RAS and mTR or empty vector (vector).
These cells were injected into SCID mice to assess the
mTR Rescue of Impaired Oncogenesis rates of tumor formation. Dramatic differences in tumor
To assess whether impaired oncogenic potential related latency were observed (Figure 4C). The mTR cultures
to the loss of telomere function, a genomic subclone produced visible tumors in 4 to 7 days following injection
encoding the mTR gene (or an empty vector) was added and grew to approximately 2 cm after 14 days, while
to the Myc/RAS cotransfections. This mTR fragment the vector cultures failed to produce tumors during the
(ªmTRº) was shown to restore telomerase activity in same period. However, it is notable that the vector cul-
mTR2/2 MEFs (Blasco et al., 1997; Chin et al., 1999 [this tures did eventually yield tumors and, once established,
issue of Cell]) and 5 of 5 Myc/RAS/mTR transformed these tumors were equally aggressive and histologically
subclones exhibited TRAP activity (data not shown). indistinguishable from the mTR expressing tumors (data
Compared to vector, the addition of mTR to Myc/RAS not shown). The rescue of oncogenic transformation and
cotransfections produced no increase in foci counts in restoration of telomerase by mTR transfection suggest
wild-type and G2 mTR2/2 INK4a2/2 MEFs and only mod- that the compromised growth properties of G5 mTR2/2
est increases in G4 mTR2/2 INK4a2/2 MEFs (Figure 4A). INK4a2/2 MEFs result primarily from a loss of telomere
In contrast, mTR cotransfection resulted in a 2- to 5.5- function. By extension, these findings also suggest that
fold increase in the rate of Myc/RAS-induced foci in the reduced tumor incidence in late-generation mTR2/2
the G5 mTR2/2 INK4a2/2 MEFs (Figures 4A and 4B). INK4a2/2 mice relates in large part to a cell-autonomous
Additionally, mTR transfection enhanced the subcloning defect due to loss of telomere function in the developing
efficiency of G5 Myc/RAS (i.e., the capacity of foci to cancer cell.
yield permanently established cell lines). The subcloning
efficiencies were 5 of 20 (25%) for Myc/RAS/vector Telomere Dynamics and Cytogenetic Profiles
(ªvectorº) cotransfections versus 13 of 21 (62%) for Myc/ in the Setting of Telomere Dysfunction
RAS/mTR (ªmTRº) cotransfections (p 5 0.008). and Tumorigenesis
To understand further the role of mTR in oncogenic The ability of late-generation mTR2/2 INK4a2/2 cells to
form tumors after extended growth periods (Figure 4Ctransformation of mTR2/2 INK4a2/2 MEFs, the latency
Cell
520
Figure 5. Telomere Dynamics in Telomerase
Positive and Negative Tumors
(A±D) Histogram profiles of the number of
probes hybridized for two mTR1/1 INK4a2/2
and two G5 mTR2/2 INK4a2/2 tumors as indi-
cated. The frequency of 0 probes hybridized
represents the percentage of free chromo-
somal termini lacking detectable telomeric
signal and does not include missing repeats
at chromosome fusion points.
(E) Metaphase spreads (top two panels) of
SCID tumors derived from Myc/RAS trans-
formed G5 mTR2/2 INK4a2/2 MEF (G5.8) with
or without telomerase reconstitution (ªmTRº
or ªvectorº, respectively). Separate chromo-
some DAPI and cy3 telomere images were
overlaid in Adobe Photoshop (Adobe Sys-
tems, Mountain View, California) and as-
signed blue and red colors, respectively.
(Bottom panels) telomere length histograms
represented by the number of probes hybrid-
ized per telomere.
and see Blasco et al., 1997) suggests the existence of per metaphase. In contrast, metaphases derived from
a collection of mTR1/1 INK4a2/2 lymphomas and fibro-telomerase-independent telomere maintenance mecha-
nisms or neutralization of cellular checkpoints elicited sarcomas revealed 0.1% signal-free ends per meta-
phase (n 5 40) (Figures 5A and 5B) and 0.03 fusionsby telomere erosion. To begin to assess these adaptive
responses, quantitative telomere length determinations per metaphase. These data indicate that primary tumor
formation in vivo can take place in the setting of severelyand cytogenetic analyses were conducted on mTR2/2
INK4a2/2 cell lines and tumors. shortened telomeres and telomere dysfunction (i.e.,
fusions).Primary Tumors
First, telomere length and cytogenetic analyses were Culture-Derived Tumors in SCID Mice
Decreased tumor incidence and focus formation in theperformed in primary tumors arising in G5 mTR2/2
INK4a2/2 and mTR1/1 INK4a2/2 mice. Telomere length setting of compromised telomere function (see above)
implies the existence of a genetic selection process thatwas measured by quantitative fluorescence in situ hy-
bridization (Q-FISH) (Zijlmans et al., 1997). As antici- enables late-generation mTR null cancer cells to survive
despite telomere dysfunction. Such genetic adaptationspated, the G5 mTR2/2 INK4a2/2 tumors possessed a
shorter mean telomere length than the mTR1/1 INK4a2/2 may not be readily evident in the analysis of a limited
pool of primary tumors (see above) or independentlytumors (Figures 5A±5D). These primary G5 mTR2/2
INK4a2/2 tumors showed chromosomal termini lacking derived Myc/RAS transformed cell lines (see below). To
study the most malignant subclones, we allowed selec-detectable hybridization signal (termed ªsignal-free
endsº). For example, a G5 mTR2/2 INK4a2/2 lymphoma tion for these cells to occur in vivo by generating tumors
in SCID mice produced from the injection of Myc/RASpossessed 5.9% signal-free ends and 1 fusion per meta-
phase, and a G5 mTR2/2 INK4a2/2 fibrosarcoma had transformed MEF cultures (e.g., SCID tumors in Figure
4C). Both telomere length and cytogenetic profiles in the1.8% signal-free ends (Figures 5C and 5D) and 1 fusion
Telomerase Deficiency Impairs Tumorigenesis In Vivo
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Table 1. Summary of Telomere Length and Cytogenetic Profiles in G5 mTR2/2 INK4a2/2 Transformed Subclones
Mean Probes Fusion per No. of
per Telomere Metaphase Metaphases Examined
G5.7 parental 323 0.6 15
7.1 vector 72 2.8 10
7.2 vector 33 2.8 10
7.3 vector 35 3.0 10
7.4 mTR 70 0.2 10
7.5 mTR 36 0.1 10
7.6 mTR 435 0.2 10
Metaphase spreads were prepared as described in Experimental Procedures, and fusions per metaphase were counted. Probes per telomere
were determined by Q-FISH as described in Experimental Procedures.
parental G5 mTR2/2 INK4a2/2 MEF cultures and tumors the 7.1 vector sample (Table 1). These findings, in combi-
nation with the cytogenetic analysis of SCID-derived tu-produced from these MEF cultures cotransfected with
either Myc/RAS/vector or Myc/RAS/mTR were ana- mors (Figure 5E), suggest that the presence of telomerase
in tumor cells can stabilize telomeres at shorter lengthslyzed. A representative metaphase for each of the ªcul-
ture-derivedº tumors is shown (Figure 5E). Tumors de- and provide genomic stability possibly via a protective
ªcapping function.ºrived from both the vector and mTR cotransformed cells
showed a striking reduction in the number of signal-free Finally, we analyzed the ability of the mTR and vector
transfected subclones to form tumors in SCID mice.chromosome termini (, 0.3% or 0.0%, respectively, n 5
15 metaphases for each) compared with the 1.7% sig- All three vector transfected subclones exhibited tumor
growth characteristics that were identical to the mTRnal-free ends in the parental culture (n 5 15) (data not
shown). Remarkably, despite this similar decrease in the transfected subclones despite the presence of shorter
telomeres and multiple fusions. For both vector and mTRnumber of signal-free ends, the vector-derived trans-
formants possessed 4 fusions per metaphase (n 5 15), transformed cells, the subcutaneous injection of 5 3 105
cells into SCID mice produced 2 cm tumors in 10 to 14whereas no fusion was observed for mTR transformants
(n 5 15) (Figure 5E, top left and right panels, respec- days (data not shown). In addition, the vector trans-
fected subclone 7.3 grew at a rate similar to the mTRtively). This is compared to an average of 0.6 fusion per
metaphase observed for the G5.8 parental cultures (n 5 transfected subclone 7.6 through four cycles of re-
peated injection into SCID mice (Data not shown).15) (data not shown). Thus, in cells with short telomeres,
tumor growth appears to select for an increase in the Rescue of Impaired Oncogenesis by SV40
Large T Antigennumber of chromosomal fusions and a decrease in the
occurrence of signal-free ends. Together, these findings Given the striking difference in cytogenetic profile be-
tween Myc 1 RAS transformed MEFs containing eithersuggest that viability in vector-derived tumors may be
enhanced through chromosomal fusions, and/or reduc- mTR or a vector control plasmid, we speculate that mTR
may be enhancing focus formation by diminishing thetion of DNA damage signals (i.e., decreased signal-
free ends). rampant genetic instability associated with telomere
dysfunction. Recent evidence has directly implicatedMyc/RAS Transformed Subclones
To further analyze the changes in telomere length and the p53-dependent DNA damage response as a key
mediator of the adverse cellular consequences (e.g.,chromosome fusions between telomerase negative and
telomerase positive transformed cells, we performed apoptosis) brought about by telomere dysfunction (Chin
et al., 1999; Karlseder et al., 1999). Abrogation of thesesimilar analyses on independently derived transformed
cell lines arising from a G5 mTR2/2 INK4a2/2 MEF cul- responses through the use of a viral oncoprotein such
as SV40 large T antigen (T-Ag) would therefore be pre-ture, G5.7. Q-FISH analysis of three Myc/RAS/mTR and
three Myc/RAS/Vector derived cell lines revealed that dicted to produce similar numbers of transformed foci
in late-generation mTR2/2 INK4a2/2 MEFs transfectedall vector metaphases possessed shorter telomeres rel-
ative to those derived from the parental G5.7 culture with either mTR or vector control plasmids. To this end,
we performed transformation assays on G5 mTR2/2(Table 1). Telomere lengths also decreased in 2 of 3
mTR subclones (7.4 and 7.5, Table 1) but increased in INK4a2/2 MEFs by cotransfecting T-Ag 1 RAS with ei-
ther vector control or mTR (Figure 6). Total number ofthe remaining subclone (7.6). Interestingly, subclone 7.6
showed long heterogeneous telomeres, reminiscent of foci for three different G5 mTR2/2 INK4a2/2 MEF cultures
were only modestly reduced compared to the mTR1/1ALT pathway cells, despite possessing telomerase ac-
tivity. Chromosomal end fusions were detected in all INK4a2/2 MEF cultures (Figure 6A). More importantly,
mTR did not significantly enhance numbers of foci forvector metaphases, with an average of 2.9 fusions per
metaphase (n 5 30). Conversely, fusions were rare in any of the three G5 mTR2/2 INK4a2/2 above that of
vector control groups. The ability of T-Ag to transformthe mTR metaphases with an average of only 0.1 fusions
per metaphase (n 5 30). Notably, although mTR sub- these late-generation mTR2/2 INK4a2/2 MEFs with or
without telomerase reconstitution with equal efficiencyclones 7.4 and 7.5 possessed a similar or shorter overall
telomere length relative to the vector subclone 7.1, both suggests that T-Ag may be capable of neutralizing cellu-
lar checkpoints downstream of telomere dysfunction.7.4 and 7.5 mTR clones exhibited far fewer fusions than
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tumorigenic growth in the setting of short telomeres can
be associated with an increase in dicentric chromosomes
(and corresponding reduction in signal-free ends). Follow-
ing very stringent tumorigenic selection (for example,
Figure 5), there appears to be a marked decrease in the
frequency of signal-free termini and a further increase
in fusions. This suggests that end-to-end fusion repre-
sents in some cases an adaptive mechanism which
serves to eliminate unprotected chromosomal termini
and thereby maintains chromosomal integrity. The for-
mation of chromosomal fusions in the G5 mTR2/2
INK4a2/2 derived primary tumor cells may represent a
similar compensatory mechanism. Only in those cases
where the fusion results in a stable Robertsonian type
chromosome is this mechanism likely to be adaptive.
Thus, such a mechanism may be more prevalent in
mouse cells than human cells, since mouse chomo-
somes are telocentric (Kipling et al., 1991).
The tight correlation between telomere maintenance
and human cancer has led to the proposed use of telo-
merase inhibition for the treatment of malignancy. We
have demonstrated that when cells have significantly
shortened telomeres, telomerase can cooperate with
c-Myc and RAS to transform cells and generate tumors.
It was shown recently that hTERT can cooperate with
Figure 6. T-Ag Partially Rescues the Ability of G5 mTR2/2 INK4a2/2 loss of tumor suppressor function and T-Ag to bypass
MEFs to Form Transformed Foci M1 and M2 checkpoints, respectively (Counter et al.,
(A) Graphic illustration of number of foci per 10 cm plate 10 days 1998; Kiyono et al., 1998). Thus, telomerase can function
after transfection of SV40 large T antigen (T-Ag) 1 RAS 1 either to enhance cellular transformation by oncogenes andempty vector (hatched) or mTR (black). MEF cultures were split 1:3
in principle could provide a rational chemotherapeutic18 hr after transfection.
target for inhibition. In established tumors, however,(B) Representative plates of the same MEF culture transfected with
T-Ag 1 RAS 1 empty vector or mTR as indicated. Plates were telomerase inhibition may lead to crisis, but adaptive
stained with 0.1% crystal violet for graphic illustration. mechanisms such as fusion and/or ALT may give rise
to survivor cells. Given the large telomeric reserve pres-
ent in the mouse genome, it is difficult to achieve a
Indeed, with complete elimination of p53 function, telo-
state of global telomere shortening analogous to crisis
mere dysfunction can in fact increase the number of
in human cells. However, analysis of vector transformed
Myc/RAS-induced foci (Chin et al., 1999).
subclones and primary G5 mTR2/2 INK4a2/2 tumor cells
indicates that transformed cells can tolerate relativelyDiscussion
high numbers of missing or very short telomeric repeats
and chromosomal fusions that are characteristic ofTelomere maintenance via telomerase reactivation or
postcrisis human cells (Counter et al., 1992). The abilityALT is a hallmark of cancer cells (Counter et al., 1992;
of SV40 large T antigen to transform late-generationKim et al., 1994; Bryan et al., 1995, 1997). Here, the
mTR2/2 INK4a2/2 cells with near similar efficiency toexperimental merits of the INK4aD2/3 model were ex-
mTR1/1 INK4a2/2 counterparts suggests that T-Ag mayploited to study the role of telomerase in transformation
deactivate checkpoints which allow for tolerance of dys-and tumorigenesis. The loss of telomere function and
functional telomeres (Chin et al., 1999). Along thesethe inability to activate telomerase reduced the cancer
lines, the response to telomere-induced crisis may beincidence by greater that 50% in vivo and enhanced
very different in cancer cells harboring intact (INK4a/survival. Notably the reduction in tumor formation was
ARF) or compromised (p53) DNA damage pathways.seen only in late generations after significant telomere
Since DNA damage, such as telomere erosion, does notshortening had occurred. Further, cell culture experi-
utilize ARF to signal to p53 (Kamijo et al., 1997; Stott etments using cells from late-generation animals demon-
al., 1998), loss of telomeric function in an INK4a/ARF nullstrated impaired colony formation, transformation, and
tumor would be predicted to lead to apoptosis through aplating efficiencies. Cytogenetic analysis indicated that
p53-dependent process. On the other hand, it is possiblethese cells had loss of telomere function. The reintroduc-
that the loss of telomere function combined with defec-tion of mTR greatly ameliorated the antioncogenic ef-
tive telomere sensing checkpoints (i.e., p53-dependentfects associated with telomere loss. Together, these
DNA damage response) may have either no effect orfindings establish an important role for intact telomeres
lead to an increase in genetic instability and enhancedand telomerase in facilitating the tumorigenic process.
malignant potential. Our recent studies suggest that theThis study also establishes that the response to telo-
absence of telomerase does indeed fuel genetic instabil-mere loss during cellular transformation is complex. In
telomerase-deficient cells, we observed that long-term ity and promote tumor formation in aging mTR2/2 mice
Telomerase Deficiency Impairs Tumorigenesis In Vivo
523
were centrifuged again and resuspended in 0.5 ml of the superna-(Rudolph et al., 1999). Thus, telomerase may play a para-
tant. Three milliliters of a 3:1 methanol:acetic acid fix solution wasdoxical role, either promoting or inhibiting tumor forma-
then added slowly with continuous bubbling to mix. The metaphasetion depending on the genetic context. Further studies
cells were then centrifuged and supernatant aspirated. Fix solution
will be required to define the genetic backgrounds re- was again used to resuspend the pellet and the cells centrifuged.
sponsible for determining which role predominates. Our This step was repeated one more time. Cells were then dropped
onto 22 mm by 22 mm glass coverslips (VWR) and allowed to airresults point to the need for further investigation into
dry overnight.the relationship between telomeres and key tumor sup-
Coverslips containing suitable metaphase chromosomes were hy-pressor pathways, particularly those involved in the re-
bridized to cy3-labeled peptide nucleic acid (PNA) probes (C3TA2)3sponse to DNA damage.
and counterstained with DAPI as previously described (Zijlmans et
al., 1997). Images were captured using CellScan software (Scanalyt-
Experimental Procedures ics, Fairfax, VA) on an Optiplex Gxpro computer (Dell, Austin, TX)
with a CH-250 16-bit, thermoelectrically cooled (240.08C) charge
Generation of mTR/INK4a Double Null Mice for Tumor Studies coupled device (CCD) camera (Photometrics, Tuscon, AZ) mounted
Mice heterozygous at both the INK4a and mTR loci were obtained on a Provis AX70 fluorescence microscope (Olympus, Melville, NY).
through crossing heterozygotes null for each individual locus to Twenty-five optical sections were captured at 100 mm z-intervals
generate mTR1/2 INK4a1/2 animals in the predicted 1:4 ratio. Double and at effective pixel size of 500 nm by 500 nm. Background was
heterozygotes produced doubly null mice again in the expected subtracted and the images exhaustively deconvoluted with an ac-
1:16 ratio. These first-generation mTR2/2 INK4a2/2 (G1) were mated quired point spread function (PSF) using EPR software (Scanalytics)
to give the second generation of telomerase deficiency (G2). This (Bertrand et al., 1998).
mating scheme was continued until the fifth generation (G5). This The TFI per telomere was determined in the program Meta-
was the latest generation of telomerase-deficient INK4a2/2 mice to morphTM by circling cy3 intensities that corresponded to telomeric
be followed, as we were unable to obtain G6 animals due to infertility positions on the DAPI image of the chromosomes. The number of
associated with late-generation mTR knockout mice. Tumor studies probes hybridized per telomere was determined by dividing the TFI
involving two-step carcinogenesis protocols were performed as pre- of each telomere by the experimentally determined TFI per probe
viously described (Serrano et al., 1996). value and then by the number of planes restored in the PDF (Femino
et al., 1998).
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